Chairs: Kirtan Ganda & Sonakshi Sharma
Long-Term Persistence with Denosumab and Bisphosphonates after Fracture and Its Association with Clinical Outcomes: A Population-Based Linked Cohort Study (#191)
1:30 PM
Longitudinal changes in bone microarchitecture during gender-affirming hormone therapy: a 24-month prospective HR-pQCT study in transgender adults (#192)
1:45 PM
Development of a National Multidisciplinary Consensus Statement on Medication-Related Osteonecrosis of the Jaw (MRONJ) and Osteoporosis in Australia (#193)
2:00 PM
Predictors of re-fracture and mortality within a secondary fracture prevention program: insights from up to 15-years follow-up (#194)
2:15 PM
The effect of osteocalcin and GPRC6A silencing on insulin sensitivity in myotubes from older women (#195)
2:30 PM
Hiding in plain sight: hypercalcaemia associated with calcium sulphate beads (#196)
2:45 PM
Trabecular bone score independently predicts minimal trauma fracture vs more-than-minimal trauma fracture in an Australian re-fracture prevention clinic cohort (#197)
2:50 PM
Management of aromatase inhibitor-associated bone loss in women with hormone receptor-positive breast cancer: a single centre experience (#198)
2:55 PM
Rates of electrolyte derangements associated with ferric derisomaltose and denosumab co-administration amongst an adult inpatient cohort in a metropolitan Australia health service (#199)
3:00 PM